Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

Hair texture changes, such as hair becoming curly, are common when using treatments like finasteride and minoxidil. Users report various experiences with these treatments, including changes in hair density and texture, with some using additional products like alfatrodial, fluridil, and pyrilutamide for hair maintenance.

The user reported subtle hair regrowth by focusing on scalp health and lifestyle changes, using Nizoral shampoo and methods to reduce inflammation and cortisol, without using finasteride, minoxidil, or other common treatments. Opinions in the conversation varied, with some skeptical of the results and others acknowledging the potential benefits of addressing scalp health and inflammation.

Diet and lifestyle changes can reduce hair shedding but won't regrow hair lost to genetic male pattern baldness. Treatments like finasteride and dutasteride are necessary for significant hair regrowth.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.